NCT04468009

Treatment of Critically Ill Patients With Covid-19 With Convalescent Plasma

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 134 (actual)
• Sponsor: Hospital de Infecciosas Francisco Javier Muniz · Other Government
• Sex: All
• Age: 18 Years – 100 Years
• Healthy volunteers: Accepted

Summary

This study aims to collect convalescent plasma and use it as experimental treatment in critically ill Covid-19 patients in order to reduce mortality and length of stay in intensive care unit.

Detailed description

This study aims to use convalescent plasma as experimental treatment in critically ill Covid-19 patients in order to reduce mortality and length of stay in intensive care unit. Donors must have anti-SARS CoV2 antibodies. Recipients must be critically ill Covid-19 patients on mechanical ventilation.

Conditions

• SARS-Associated Coronavirus
• Covid19
• SARS-CoV Infection

Interventions

Type	Name	Description
BIOLOGICAL	Convalescent plasma	Convalescent plasma from patients recovering from Covid-19 and which had anti-SARS-Cov-2 antibodies

Timeline

• Start date: 2020-06-25
• Primary completion: 2021-01-19
• Completion: 2021-06-19
• First posted: 2020-07-13
• Last updated: 2021-08-25

Locations

1 site across 1 country: Argentina